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Abstract
Background: Thyroid nodules are common and often benign, although prove to be malignant upon surgical
pathology in 5–15% of cases. When assessed with ultrasound-guided fine-needle aspiration (USFNA), 15–30% of the
nodules yield an indeterminate result. The Afirma® gene expression classifier (AGEC) was developed to improve
management of indeterminate thyroid nodules (ITNs) by classifying them as “benign” or “suspicious.” Objectives
were (1) to assess the performance of the AGEC in two Canadian academic medical centres (2), to search for
inter-institutional variation and (3) to compare AGEC performance in Canadian versus American institutions.
Methods: We undertook a retrospective cohort study of patients with indeterminate cytopathology (Bethesda
Class III or IV) as per USFNA who underwent AGEC testing. We reviewed patient demographics, cytopathological
results, AGEC data and, if the patient underwent surgery, results from their final pathology.
Results: In total, we included 172 patients with Bethesda Class III or IV thyroid nodules underwent AGEC testing,
109 in Montreal, Quebec and 63 in St. John’s, Newfoundland, in this study. Among the nodules sent for testing,
55% (60/109) in Montreal and 46% (29/63) in St. John’s returned as “benign.” None of these patients underwent
surgery. On the other hand, 45% (49/109) nodules in Montreal and 54% (34/63) in St. John’s were found to be
“suspicious,” for a total of 83 specimens. Seventy seven of these patients underwent surgery. Both in Montreal
and St. John’s, the final pathology yielded malignant thyroid disease in approximately 50% of the specimens
categorized as “suspicious.” Since 2013, no patient diagnosed with a benign nodule as per AGEC testing was
found to harbor a malignant thyroid nodule on follow-up.
Conclusions: Molecular analysis is increasingly used in the management of indeterminate thyroid nodules. This
study highlights the experience of two Canadian centres with AGEC testing. We found inter-institutional
variability in the rate of nodules returning as “benign,” however we found similar rates of confirmed malignancy
in nodules returning as “suspicious.” According the literature, results for AGEC testing in two Canadian institutions
align with results reported in American centres.
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Background
In the past three decades, an important rise in the inci-
dence of thyroid cancer has been noted worldwide [1].
Currently, ultrasound-guided fine-needle aspiration
(USFNA) is the diagnostic tool of choice for evaluation
and management of thyroid nodules [2, 3]. However, in
approximately 15–30% of USFNAs, the cytological re-
sults are found to be indeterminate [4]. Indeterminate
thyroid nodules (ITN) include, as per the Bethesda
System for Reporting Thyroid Cytopathology (BSRTC),
nodules that are Bethesda Class III: atypia of undeter-
mined significance or follicular lesion of undetermined
significance (AUS/FLUS) or Bethesda Class IV: follicular
neoplasm (FN). A large number of patients with ITNs
subsequently undergo diagnostic hemi-thyroidectomy.
Studies have shown an overall postoperative malignancy
rate ranging between 15 and 30% [5].
Molecular analysis of USFNA specimens from ITNs
has gained in popularity recently as an adjunct to micro-
scopic cytological evaluation. Many molecular markers
have shown promise, such as BRAF and RAS mutations.
Although these markers demonstrate a high specificity
and positive predictive value, they have limited sensitiv-
ity [6]. A test with a poor sensitivity cannot rule out a
diagnosis with certainty. Thus, Chudova et al. set out to
find genetic markers with a higher sensitivity in order to
develop a test that would confirm benignity of an ITN
with greater fidelity [4].
The Afirma® gene expression classifier (AGEC) is a
diagnostic test that measures the expression of 167
gene transcripts in specimens of thyroid tissue collected
by fine-needle aspiration. It classifies the aspirate as ei-
ther “benign” or “suspicious.” In a validation study by
Alexander et al., the AGEC test was shown to have a
sensitivity exceeding 90% and a negative predictive
value (NPV) of 94% for both Bethesda Class III and IV
nodules [6]. Our study aimed to evaluate the experience
with the AGEC test in two Canadian centres: Montreal,
Quebec and St. John’s, Newfoundland. To our know-
ledge, there are no reports in the literature describing
the experience of a Canadian centre that uses the
AGEC test. We sought to assess the performance of the
AGEC test in both centres, to search for inter-
institutional variability, and to compare our results with
data published from studies in the United States.
Methods
Study design
The principal investigators undertook a retrospective co-
hort study of patients with cytologically indeterminate
thyroid nodules who underwent AGEC testing between
2013 and 2015 in two Canadian medical centres: in
Montreal, Quebec and in St. John’s, Newfoundland.
Multi-center ethics review approval was obtained from
Research Ethics Committees at the Jewish General Hos-
pital in Montreal, Québec and at St. Clare’s Mercy Hos-
pital in St. John’s, Newfoundland.
Patient selection
Patients included were over the age of 18, with one or
more thyroid nodules exceeding 1 cm in diameter on
ultrasound. The patients included were those with inde-
terminate cytopathology (Bethesda Class III or IV) as per
USFNA. In Montreal, the cytopathology was performed
using cell blocks and a Bethesda score was assigned by the
pathologist. All USFNA cytology was read internally by
experienced thyroid nodule cytopathologists. Upon receipt
of indeterminate cytopathology, patients were counseled
as to the different management options (surgery, close fol-
low up, and AGEC testing). Patients were counseled at
length as to the benefits and pitfalls of each option. Ex-
cluded patients were those awaiting surgery or awaiting
final pathology results at the time of our data
collection.
Sample collection
Upon obtaining patient consent, a trained physician per-
formed the USFNA to collect the samples for AGEC
testing. Proper preservation and packing of the samples
was ensured. Each sample was sent via courier to Vera-
cyte’s Clinical Laboratory Improvement Amendments in
San Francisco, California. Communication was maintained
with customs throughout the process, and receipt con-
firmation was obtained upon arrival of the specimens.
Data collection
For each patient the following was reviewed: patient
demographics, cytopathological results, AGEC data and,
if the patient underwent surgery, results from their final
pathology.
Statistical analysis
Statistical analysis was performed using MedCalc ver-
sion 12.2. When appropriate, the chi-square test was
used. P-values less than 0.05 were considered statisti-
cally significant.
Also, we calculated AGEC-benign call rate, representing
the number AGEC tests returning as benign, and positive
predictive value (PPV), representing true positives divided
by the number of GEC-suspicious results and compared
these to values obtained in the study by Alexander et al. to
search for inter-institutional variability.
Results
In total, 172 patients with Bethesda Class III or IV thy-
roid nodules underwent AGEC testing were included in
this study, 109 in Montreal and 63 in St. John’s. Table 1
shows the distribution of nodules, according to Bethesda
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classification. In Table 2, we find the AGEC results by
institution. In Montreal, 55% (60/109) of nodules
returned as “benign.” In St. John’s, 46% (29/63) of nod-
ules returned as “benign.” In St. John’s, ten nodules were
returned initially as “no result.” Following this, in five
patients, AGEC was repeated. Three yielded results,
however two yielded “no results” a second time. Four
patients opted not to repeat AGEC but simply to
undergo management based on repeat USFNA. Finally,
one patient was lost to follow up and was excluded from
the study. Only the patients who had a “benign” or “sus-
picious” result were included in our statistical analysis,
however we thought it was important to include these
results. In Montreal, this occurred in only one instance;
the specimen was collected again and a result obtained.
Overall, 83 out of 172 specimens were classified as
“suspicious” according to the AGEC test. Seventy seven
patients with “suspicious” nodules had undergone sur-
gery at the time of our data collection, with six patients
having decided to not undergo surgery despite the suspi-
cious result. Among the 77 patients who underwent sur-
gery, the ratio of benign to malignant final pathology is
nearly 50%. More precisely, in Montreal, 48% (21/44) of
“suspicious” nodules were malignant on final pathology,
and 52% (17/33) in St. John’s. The summary of these
results can be found in Tables 3.
Finally, we evaluated pre-test probability (or disease
prevalence) and the post-test probability of a positive
AGEC test. The disease prevalence of malignancy among
all Bethesda 3 and 4’s (among all patients, not only this
particular group of patients who elected or were chosen
to undergo AGEC testing) was 32% in Montreal and 46%
in St. John’s. The post-test probability of a positive test
(which is the PPV) was 45.71% [95% confidence interval
(CI) 29.22–63.13] in Montreal and 51.51% [95% CI 33.85–
68.83] in St. John’s. Finally, since the start of the study, no
patients with benign results as per AGEC testing were
found to harbor a malignant thyroid nodule on follow-up.
Discussion
Interest in the combination of microscopic thyroid cytopa-
thology and molecular analysis has increased significantly
in recent years. Molecular analysis has gained popularity
with the discovery that up to two-thirds of follicular cell-
derived thyroid malignancies harbor a genetic mutation
[7–9]. The AGEC test is used to reclassify cytologically in-
determinate thyroid nodules, categorizing the nodules as
either “benign” or “suspicious” based on the expression
pattern of mRNA extracted from the USFNA samples.
The test uses an algorithm comprised of 167 genes. 142 of
them are part of the main classifier to separate benign ver-
sus malignant disease; whereas the other 25 genes are used
to filter out rare neoplasms. [6] The test is meant to pre-
dict benignity and avoid unnecessary diagnostic surgery
and is reported to have a high sensitivity as well as a high
negative predictive value. Our study evaluated the experi-
ence of two Canadian centres using the AGEC test. To
date, studies of the AGEC test have included two large
clinical validation studies [4, 6], three studies evaluating
clinical utility [10–12] one analytical validation study [13],
as well as a quality of life and cost-effectiveness study [14].
In addition, there have been over a dozen single institution
reports recounting experiences with the test. [15–20]
However, these studies were performed by investigators in
the United States. To our knowledge, there are no reports
published describing the use of this test in Canada.
We investigated 172 patients with indeterminate thy-
roid nodule cytology who underwent Afirma® testing. In
total, 89 nodules-60 (55%) in Montreal and 29 (46%) in
St. John’s-returned as “benign” as per AGEC testing.
This result significantly impacted patient management,
as no patient underwent surgery. Traditionally, the vast
majority of these patients would have undergone a diag-
nostic hemi-thyroidectomy at these centres. Instead,
these patients avoided surgery and are currently man-
aged with regular ultrasound follow-up. Unfortunately,
the long-term outcome for these patients is still
unknown.
Additionally, 45% of patients in Montreal and 54% of
patients in St. John’s had “suspicious” results as per the
AGEC test. In Montreal, 48% of “suspicious” nodules
were malignant on final pathology, and 52% in St. John’s.
In reality, receiving a “suspicious” AGEC test in our
Canadian cohort conferred a risk of malignancy of
approximately 50%, which is greater than the 5–15%
Table 1 Thyroid nodule Bethesda classification in both centres
Nodule Class B3 B4 Total
Montreal 84 (77%) 25 (23%) 109
St. John’s 21 (33%) 42 (67%) 63
172
Table 2 Afirma® GEC results, by centre
GEC benign GEC suspicious GEC no result Total
Montreal 60 (55%) 49 (45%) 0a 109
St. John’s 29 (41%) 34 (49%) 7a (10%) 70
179
aSee further explanation in result section. AGEC tests yielding no results were
excluded from our statistical analysis
Table 3 Final pathology results of patients with “suspicious”
Afirma® GEC results
Underwent surgery Benign Malignant
Montreal 44 23 (52%) 21 (48%)
St. John’s 33 16 (48%) 17 (52%)
Total 77 39 (51%) 38 (49%)
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(Bethesda 3) or the 15–30% (Bethesda 4) suggested in
the Bethesda classification. We must keep in mind that
this does not indicate that 50% of B3/B4’s in our centres
are malignant, because many were removed from this
part of the analysis after having been classified as “be-
nign” by AGEC. The final pathology outcomes of “suspi-
cious” nodules were similar in St. John’s and Montreal.
Indeed, in the above-mentioned study by Alexander et
al., the rates of malignant final pathology varied greatly
between sites, with malignancy rates as low as 33% and
as high as 80% at certain centres. However, multiple
single-institution studies, such as that of Lastra et al.
and Marti et al., have shown approximately 50% malig-
nancy rates in “suspicious” nodules as per AGEC, mir-
roring our study [15, 18]. As most patients with a
“suspicious” nodule undergo surgery, it implies that
AGEC testing in these cases did not necessarily impact
management, since traditionally most of these patients
would have undergone diagnostic surgery. Indeed, when
we compared patients from our own cohort with ITNs
with “suspicious” results as per AGEC testing compared
to those in whom AGEC testing was not performed, the
final surgical pathology outcomes were nearly identical.
There is a 9% difference in rates of “benign” nodules
as per AGEC between institutions. Data published by
Veracyte stated that approximately 50% of samples sub-
mitted are reported as benign. A slightly higher rate was
found in Montreal (55% of specimens returned as
“benign”), and a slightly lower number (46%) of benign
results were obtained in St. John’s. This discrepancy in
benign rates is found throughout the literature. For ex-
ample, a community-based practice study by Harell et al.
reported a 34% benign rate, and a study by McIver et al.,
performed in two academic centres, reported that only
27% of samples returned as “benign” [19, 20]. Another
study, published by Alexander et al. in 2013, assessed
339 FNA samples collected from five different academic
medical centres. Nearly all patients enrolled were either
a Bethesda Class 3 or 4, with eight patients having FNA
cytology “suspicious for malignancy”. In this large study,
significant variability of “benign” AGEC results were
noted between sites, ranging between 38 and 71% [12].
In our study, the variability could in theory be attributed
to difference in patient cohorts. For example, St. John’s
had more patients with Bethesda Class IV nodules com-
pared to the patients in Montreal. It is also possible that
the prevalence of thyroid cancer was greater in the pa-
tient population studied in St. John’s.
Finally, in the pivotal validation study published in
2012 by Alexander et al., the AGEC test was found to
have a sensitivity of 90%, a specificity of 53% and a
NPV of 95% [6]. In our study, due to lack of surgical
follow-up among “benign,” we cannot assess a true
NPV. The high NPV achieved by Alexander et al.
cannot necessarily be replicated in all clinical scenar-
ios, as NPV is dependent on prevalence of disease in
a given population.
Limitations
Our study has several limitations. First is the lack of sur-
gical follow-up for patients with “benign” AGEC results.
Although these patients are followed with regular ultra-
sound examinations in both centres, it will take several
years before we know the true nature of these thyroid
nodules. Another limitation in our study is a possible
lack of concordance between cytological reporting at our
centres. We found slightly different rates of benign and
malignant results, and suspect discordance in pathology
and prevalence of malignancy among the populations
studied. Finally we make a note regarding the rate of “no
result” specimens. The team in St. John’s discussed this
issue with the company and in the end, it could not be
explained. Various needle sizes, including 27 gauge, 25
gauge and 22 gauge needles were tried to mitigate this
problem, both with and without aspiration, and did not
seem to have an impact on outcomes.
Conclusion
The results from our study demonstrate that AGEC test-
ing may be a useful adjunct to microscopic cytological
testing when evaluating indeterminate thyroid nodules.
We found variability between the benign rates in both
sites, but the overall results are comparable to previously
published studies. Further long-term follow-up of these
patients is needed in order to confirm the usefulness
and safety of this test in Canada, however, to date, the
test appears safe and in our cohort, no patients have
with a “benign” nodule as per AGEC have presented
with malignant thyroid disease. For now, AGEC testing
shows promise, but neither cytological nor genetic test-
ing alone should direct management of a patient with a
thyroid nodule.
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